Cortés, J., Saglio, G., Geissler, J., Mayer, J., Etienne, G., Fillitz, M., Casterá, E. M., Kapoor, S., Cardoso, A. P., Okoroji, U., Sarac, A., Hoch, M., Quenet, S., Hughes, T. (2025). High rates of deep molecular response (DMR) in patients (pts) with chronic myeloid leukemia in chronic Phase (CML-CP) who have not achieved dmr after ≥1 year of prior imatinib (IMA) in the asciminib (ASC) monotherapy arm of the Phase 2 ASC4MORE study. Blood. https://doi.org/10.1182/blood-2025-5552